MEI Pharma Raises $100m, Launches Litecoin Treasury Strategy

MEI Pharma has acquired Litecoin and launched a $100m institutional treasury strategy. The company has also filed for a common stock offering of up to $100 million and received $99.999401 million in funding from various investors. MEI Pharma has reported Q3 cash position and Q2 earnings results, and has engaged Oppenheimer & Co. to evaluate strategic alternatives.

Title: MEI Pharma Launches $100M Institutional Treasury Strategy with Litecoin Acquisition

MEI Pharma, Inc. (NASDAQ: MEIP) has made a significant move in the financial landscape by acquiring 929,548 Litecoin (LTC) tokens and launching a $100 million institutional treasury strategy. The acquisition, valued at approximately $110.4 million as of August 4, 2025, positions MEI as the first U.S.-listed public company to adopt Litecoin as a primary reserve asset [1].

The strategic initiative is built on digital asset infrastructure and long-term capital innovation. The move is supported by GSR, a leading crypto investment firm, and guided by Litecoin Creator and MEI Board member Charlie Lee. Lee emphasized that Litecoin's reliability, efficiency, and broad-based adoption make it an ideal choice for treasury and reserve allocation [1].

MEI's treasury strategy leverages Litecoin's scalability and reliability, which have been proven over 13 years of uninterrupted uptime. The low fees and fast settlement times of Litecoin make it an attractive option for treasury management. Additionally, Litecoin's integration into platforms like BitPay, Robinhood, PayPal, and Venmo further underscores its broad-based adoption and potential for widespread use [1].

In addition to the Litecoin acquisition, MEI Pharma has also filed for a common stock offering of up to $100 million. The company received $99.999401 million in funding from various investors, reflecting the market's confidence in its strategic initiatives [2].

MEI Pharma's Q3 cash position and Q2 earnings results have been reported, providing investors with a clear picture of the company's financial health. The company has also engaged Oppenheimer & Co. to evaluate strategic alternatives, indicating a proactive approach to future growth and innovation [2].

The integration of Litecoin into MEI Pharma's treasury strategy reflects a forward-thinking approach to governance, resilience, and financial innovation. This move is part of the company's broader institutional treasury initiative, which could include the commencement of Litecoin mining activities and long-term innovation in capital structure and financial technology [1].

References

[1] https://www.morningstar.com/news/business-wire/20250805082856/mei-pharma-acquires-litecoin-launches-100m-institutional-treasury-strategy-with-charlie-lee-and-gsr-advising

[2] https://www.stocktitan.net/news/MEIP/mei-pharma-acquires-litecoin-launches-100m-institutional-treasury-hf3s5d21nt80.html